BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...
Anthos was founded in 2019 by Novartis and the private equity firm Blackstone Life Sciences. Its most advanced drug candidate, abelacimab, is a monoclonal antibody designed to prevent strokes and ...
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Ares, CD&R and Neuberger Berman target retail apparel; Life science companies ripe for PE investment
In early January came news that Marquee Brands, which is backed by Neuberger Berman , acquired Laura Ashley, the iconic London-based brand that sells home furnishings and fashion items. The seller was ...
Effective Jan. 1, 2025, comanager Stephen Sullens stepped down from Blackstone Alternative Multi-Strategy and retired from the industry. On the same day, Stephen Zhu, managing director of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback